IRONWOOD PHARMACEUTICALS INC
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston, Commonwealth of Massachusetts, on the 26 th day of February 2026.
| | ||
|---|---|---|
| | Ironwood Pharmaceuticals, Inc. | |
| | By: | /s/ Thomas McCourt |
| | | Thomas McCourt |
| | | Chief Executive Officer |
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the date indicated.
| Signature | | Title | | Date |
|---|---|---|---|---|
| | | | | |
| /s/ Thomas McCourt | | Chief Executive Officer and Director (Principal Executive Officer) | | February 26, 2026 |
| Thomas McCourt | | | ||
| /s/ Gregory Martini | | Senior Vice President, Chief Financial Officer (Principal Financial Officer) | | February 26, 2026 |
| Gregory Martini | ||||
| /s/ Ronald Silver | | Senior Vice President, Corporate Controller & Chief Accounting Officer (Principal Accounting Officer) | | February 26, 2026 |
| Ronald Silver | | | ||
| | | | | |
| /s/ Julie H. McHugh | | Chair of the Board | | February 26, 2026 |
| Julie H. McHugh | | | ||
| | | | | |
| /s/ Mark Currie | | Director | | February 26, 2026 |
| Mark Currie | | | ||
| | | | | |
| /s/ Alexander Denner | | Director | | February 26, 2026 |
| Alexander Denner | | | ||
| | | | | |
| /s/ Jon Duane | | Director | | February 26, 2026 |
| Jon Duane | | | ||
| | | | | |
| /s/ Marla Kessler | | Director | | February 26, 2026 |
| Marla Kessler | | | ||
| | | | | |
| /s/ Catherine Moukheibir | | Director | | February 26, 2026 |
| Catherine Moukheibir | | | ||
| | | | | |
| /s/ Jay P. Shepard | | Director | | February 26, 2026 |
| Jay P. Shepard | | | ||
| | | | | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.